WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells

Haematologica

Volumn 90, Issue 3, 2005, Pages 326-334

  Elmaagacli, Ahmet H ^a   Koldehoff, Michael ^a   Peceny, Rudolf ^a   Klein Hitpass, Ludger ^a   Ottinger, Helmut ^a   Beelen, Dietrich W ^a   Opalka, Bertram ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

BCR ABL; Small interfering RNA; WT1

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; SMALL INTERFERING RNA; WT1 PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PROTEIN METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; WT1 PROTEINS;

EID: 15244358400     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blasts. Leukemia 1994; 12:2138-43.
2. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms' tumor gene WT1. Proc Natl Acad Sci USA 1991;88:9618-22.
3. rd, Morris JF, Tournay OE, Cook DM, Curran T. Binding of the Wilms' tumor locus zinc finger protein to EGR-1 consensus sequence. Science 1990;250:1259-62.
4. rd. Transcriptional repression mediated by the WT1 Wilms' tumor gene product. Science 1991;253:1550-3.
5. rd. Repression of the insulin-like growth factor II gene by the Wilms' tumor suppressor WT1. Science 1992;257:674-7.
6. rd. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 1993;268:21271-5.
7. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
8. Wilda M, Fuchs U, Wössmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference. Oncogene 2002;21:5716-24.
9. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M. Specific inhibition of BCR-ABL gene expression by small interfering RNA. Blood 2003;101:1566-9.
10. Wohlbold L, Van Der Kuip H, Miething C. Inhibition of BCR-ABL gene expression by small interfering RNA sensitizes for imatinib mesylate (ST571). Blood 2003;102:2236-9.
11. Elmaagacli AH, Freist A, Hahn M. Estimating the relapse stage in chronic myeloid leukemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts detected using a new real-time polymerase chain reaction method. Br J Haemtol 2001;113:1072-5.
12. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996;88:2775-9.
13. Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW. The detection of WT1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 2000;25:91-6.
14. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, et al. Aberrant over expression of the Wilms' tumor gene (WT1) in human leukemia. Blood 1997;89:1405-12.
15. Menke AL, van der Eb AJ, Jochemsen AG. The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? Int Rev Cytol 1998;181:151-212.
16. Sugiyama H. Cancer immunotherapy targeting WT1 protein. Int J Hematol 2002;76:127-32.
17. Müller L, Knights A, Pawelec G. Synthetic peptides derived from Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells. The Hematol J 2003;4:57-66.
18. Svedberg H, Richter J, Gulberg U. Forced expression of the Wilms' tumor (WT1) gene inhibits proliferation of human hematopoietic CD34 (*) progenitor cells. Leukemia. 2001;15:1914-22.
19. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, et al. Growth inhibition of human leukemic cells WT1 (Wilms' tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996;87:2878-84.
20. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003;270:1628-44.
21. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115-21.
22. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, et al. Very low frequencies of human normal CD34* haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukemia cells. Br J Haematol 2002;116:409-20.
23. Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, et al. Wilms' tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with fibrosis. Int J Hematol 2003;78:56-61.
24. Ji J, Wernli M, Klimkait R, Erb F. Enhanced gene silencing by the application of multiple specific small interfering RNAs. FEBS Lett 2003;552:247-52.
25. Leu YW, Rahmatpanah F, Shi H, Wei SH, Liu JC, Yan PS. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res 2003;63:6110-5.